CGE Partners Invests in Datapharm

Inflexion Partnership Capital Invests £434m in GlobalData's Healthcare Business

December 1, 2023

Data & Analytics

Inflexion's Partnership Capital has agreed to make a £434 million minority equity investment to carve out GlobalData Plc's Healthcare division as a standalone business in a deal valuing the unit at £1.1 billion. GlobalData will retain majority ownership while partnering with Inflexion to accelerate organic growth, product and content investment, cross-selling, and selective M&A.

CGE Partners Invests in Ethixbase360

September 16, 2021

Cloud & SaaS

CGE Partners has made a growth investment in Ethixbase360, a London-based provider of SaaS third-party risk assessment and supply-chain ESG compliance solutions. CGE will partner with Ethixbase360’s management team to support international expansion, future M&A and new product development as the company scales.

Symeres Acquires DGr Pharma

September 15, 2025

Healthcare Services

Symeres has acquired DGr Pharma to strengthen its early‑stage drug development and regulatory consultancy capabilities, accelerating IND‑enabling services for biopharma clients. The deal is supported by Keensight Capital, which backs Symeres and aims to expand the platform's integrated CRDMO offering across discovery and early clinical development.

Nautic Partners Makes Strategic Growth Investment in EmpiRx Health

August 31, 2021

Healthcare Services

Nautic Partners has made a strategic growth investment in EmpiRx Health, the clinically driven, value-based pharmacy benefit manager (PBM). The capital will support EmpiRx’s expansion of its tech-enabled clinical innovation and care models to broaden market reach and drive improved patient outcomes and cost savings for plan sponsors.

Partners Group Acquires Pharmathen from BC Partners

July 19, 2021

Pharmaceuticals

Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.

ProPharma Group Acquires Diamond Pharma Services

March 2, 2021

Healthcare Services

ProPharma Group, a portfolio company of Odyssey Investment Partners, has acquired Diamond Pharma Services, a UK-based regulatory affairs, pharmacovigilance, and compliance consultancy. The deal expands ProPharma's global regulatory and pharmacovigilance capabilities and adds Diamond's ~85+ experts and UK footprint to ProPharma's existing suite of services.